Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
Technology appraisal guidance
Reference number: TA1122
Published:
This appraisal was discussed by the NICE Technology Appraisal Committee on 13 August 2025. At that meeting the Committee requested additional analyses from the company.